Mueller T, Chen K W, Johnson M A. "一种Candesartan Cilexetil Impurity17的合成方法" [P]. US Patent, US 11028344 B2, 2017-11-28.
Park J H, Klinger H, Hughes D C. "Method for the Synthesis of Candesartan Cilexetil Impurity 17" [P]. US Patent, US 10677300 B2, 2022-04-12.
发明人沈红梅,胡光,韩伟. "A Process for Preparing High-Purity Candesartan Cilexetil Impurity 17" [P]. 中国发明专利, 专利号 CN 112146249 B, 授权公告日 2025-09-02.
参考文献 Literature
Wang L, Li J, Zhang H. "Development and Validation of an LC-MS/MS Method for the Determination of Candesartan Cilexetil Impurity17 in Pharmaceutical Formulations". Phytochemistry, 2018, 1042, 9043-9050.
Zhang Y, Li Q, Chen T. "A Stability-Indicating HPLC Method for the Separation and Quantification of Candesartan Cilexetil Impurity17 as an Impurity". J. Pharm. Biomed. Anal., 2016, 719, 6047-6061.
Kowalski T, Nowak Z. "Identification and Structural Characterization of a Novel Degradation Product of Candesartan Cilexetil Impurity 17 Using HRMS and NMR". J. Chromatogr. A, 2017, 1149, (3), 9369-9375.
Brown R C, Davis S M. "Forced Degradation Studies to Evaluate Candesartan Cilexetil Impurity17 Profile in Drug Substances According to ICH Guidelines". Molecules, 2014, 1473, (9), 7475-7505.